Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Neogenomics Inc. (NASDAQ: NEO) closed at $13.96 up 0.29% from its previous closing price of $13.92. In other words, the price has increased by $0.29 from its previous closing price. On the day, 1.19 million shares were traded. NEO stock price reached its highest trading level at $14.364 during the session, while it also had its lowest trading level at $13.5143.
Ratios:
For a deeper understanding of Neogenomics Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.22 and its Current Ratio is at 7.48. In the meantime, Its Debt-to-Equity ratio is 0.66 whereas as Long-Term Debt/Eq ratio is at 0.65.
On December 29, 2023, BTIG Research reiterated its Buy rating and also upped its target price recommendation from $25 to $21.
Stephens Upgraded its Equal-Weight to Overweight on August 21, 2023, while the target price for the stock was maintained at $18.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 04 ’24 when TETRAULT LYNN A. sold 6,112 shares for $15.97 per share. The transaction valued at 97,579 led to the insider holds 50,062 shares of the business.
Olivo Alicia C sold 2,587 shares of NEO for $38,713 on Feb 15 ’24. The General Counsel now owns 34,866 shares after completing the transaction at $14.96 per share. On Nov 17 ’23, another insider, Olivo Alicia C, who serves as the General Counsel of the company, sold 2,669 shares for $18.39 each. As a result, the insider received 49,083 and left with 37,140 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEO now has a Market Capitalization of 1782859520 and an Enterprise Value of 1983862528. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.92 while its Price-to-Book (P/B) ratio in mrq is 1.89. Its current Enterprise Value per Revenue stands at 3.249 whereas that against EBITDA is -96.731.
Stock Price History:
The Beta on a monthly basis for NEO is 1.12, which has changed by -0.033910036 over the last 52 weeks, in comparison to a change of 0.23568535 over the same period for the S&P500. Over the past 52 weeks, NEO has reached a high of $21.22, while it has fallen to a 52-week low of $11.03. The 50-Day Moving Average of the stock is -7.05%, while the 200-Day Moving Average is calculated to be -9.26%.
Shares Statistics:
For the past three months, NEO has traded an average of 940.58K shares per day and 1144280 over the past ten days. A total of 127.37M shares are outstanding, with a floating share count of 126.20M. Insiders hold about 1.15% of the company’s shares, while institutions hold 99.11% stake in the company. Shares short for NEO as of 1713139200 were 7639948 with a Short Ratio of 8.12, compared to 1710460800 on 7289197. Therefore, it implies a Short% of Shares Outstanding of 7639948 and a Short% of Float of 8.32.
Earnings Estimates
The current market rating for Neogenomics Inc. (NEO) reflects the collective analysis of 11.0 analysts closely monitoring its performance.On average, analysts expect EPS of -$0.01 for the current quarter, with a high estimate of $0.02 and a low estimate of -$0.06, while EPS last year was -$0.05. The consensus estimate for the next quarter is $0.0, with high estimates of $0.02 and low estimates of -$0.05.
Analysts are recommending an EPS of between $0.08 and -$0.19 for the fiscal current year, implying an average EPS of -$0.01. EPS for the following year is $0.14, with 12.0 analysts recommending between $0.2 and $0.06.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $162.36M this quarter.It ranges from a high estimate of $164M to a low estimate of $160.4M. As of the current estimate, Neogenomics Inc.’s year-ago sales were $137.42MFor the next quarter, 12 analysts are estimating revenue of $166.58M. There is a high estimate of $169M for the next quarter, whereas the lowest estimate is $164.72M.
A total of 13 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $659M, while the lowest revenue estimate was $651M, resulting in an average revenue estimate of $654.77M. In the same quarter a year ago, actual revenue was $591.64MBased on 12 analysts’ estimates, the company’s revenue will be $718.62M in the next fiscal year. The high estimate is $727.63M and the low estimate is $707.1M.
